1. There was no significant difference in metastasis-free survival between the ADT and non-ADT groups over 10 years. 2. Adverse ...
1. Concurrent/adjuvant androgen-deprivation therapy has improved metastatic-free survival compared to neoadjuvant/concurrent androgen-deprivation therapy. 2. The statistical significance was mainly seen ...
1. 5-year progression-free status was greatest in group 3 (triple therapy) and lowest in group 1 (pelvic bed radiotherapy alone). ...
1. A combination of androgen deprivation therapy, docetaxel, and abiraterone (“triplet therapy”) had the best overall survival and progression-free survival ...
1. Bone mineral density testing was associated with a significant decreased risk of developing major osteoporotic fractures among older men ...
1. Abiraterone acetate plus standard treatment significantly increased length of metastasis-free survival in men with non-metastatic prostate cancer compared to ...
1. In this retrospective cohort study, there was no significant difference in all-cause mortality between patients with prostate cancer and ...
1. Enzalutamide along with androgen-deprivation therapy was shown to significantly increase median overall survival among men with non-metastatic, castration-resistant prostate ...
1. Enzalutamide along with androgen-deprivation therapy was shown to significantly increase median overall survival among men with non-metastatic, castration-resistant prostate ...
Androgen deprivation therapy (ADT) is used in the treatment of prostate cancer, either alone or in combination with other treatment ...
